Pasithea Therapeutics Corp. (KTTA) Risk Assessment & Volatility Analysis

Comprehensive risk assessment and volatility analysis for KTTA including beta analysis, market risk, financial risk, and investment risk evaluation. Understand the potential risks and rewards of investing in KTTA stock with expert risk management insights.

Risk Assessment Summary

High price volatility

Low market volatility (Beta < 0.8)

Governance Risk

Overall Risk Score

N/A

Audit Risk

N/A

Board Risk

N/A

Compensation Risk

N/A

Shareholder Rights Risk

N/A

Market Risk

Beta (5Y Monthly)

0.29Low

52-Week Change

-50.51%Low

S&P 500 52-Week Change

13.26%Very High

Short Interest Ratio

0.24Low

Short % of Float

0.32%Low

Volatility (Annualized)

172.56%Very High

Financial Risk

Total Debt

$0.00

Enterprise Value

$6.82M

Profit Margins

0.00%Very High

Earnings Growth (QoQ)

N/A

Net Income to Common

$-13494476.00

Book Value

$1.64

Risk vs Reward Analysis

Risk Factors

Beta: 0.29

Volatility: 172.56%

Short Interest: 0.24

Potential Rewards

52-Week Change: -50.51%

Earnings Growth: N/A

Profit Margin: 0.00%